Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026
Bitget2026/10/01 20:06- Mineralys Therapeutics announced new clinical and preclinical lorundrostat data will be presented at AHA Hypertension Scientific Sessions 2026 on Oct. 7-11.
- A featured oral presentation will cover the Explore-OSA randomized crossover trial in obstructive sleep apnea with hypertension, focusing on efficacy and safety.
- Additional presentations will highlight analyses from the Launch-HTN study in uncontrolled and resistant hypertension, including responder outcomes.
- Preclinical findings slated for posters indicate lorundrostat reduced cardiorenal injury in a rat model, separate from blood pressure lowering.
- Market-use research will review real-world spironolactone treatment patterns and adherence to mineralocorticoid receptor antagonists in resistant hypertension.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BoJ’s Uchida: AI has become a major focus among central banks, including at BoJ policy meetings
Nikkei 225 Index surpasses 70,000 points for the first time since July 6
NIL has surged more than 17% in 24 hours, and the current price is 0.096 USDT.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Current Spread in Yield Basis Points Germany 3.475 % Australia 5.347 % 187.2 Belgium 4.339 % 86.4 Canada 3.944 % 46.9 Denmark 3.268 % -20.7 France 4.866 % 139.1 Italy 4.604 % 113.0 Japan 3.100 % -37.5 Netherlands 3.577 % 10.2 Spain 4.087 % 61.2 Sweden 3.146 % -32.9 U.K. 5.369 % 189.4 U.S. 5.267 % 179.2 Source: Tullett Prebon via FactSet (END) Dow Jones Newswires October 04, 2026 21:10 ET (01:10 GMT)
Crypto prices
More
